Navigation Links
Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Date:3/7/2013

SAN DIEGO and FOUNTAIN VALLEY, Calif., March 7, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC) and other cancers.  If the transaction is consummated, the combined company would form an oncology franchise of potential products with Phase 2 data for multiple solid tumor indications as well as two synergistic drug discovery and development platforms.

IGDRASOL's lead compound, Cynviloq™, is a next-generation micellar diblock copolymeric paclitaxel formulation creating a stable, easy-to-administer injectable for effective delivery of drug into tumor tissues.  Cynviloq™ is currently approved and marketed in several countries, including South Korea for MBC and NSCLC under the trade name Genexol-PM®, and has completed Phase 2 testing for potential advancement into registration trials in the U.S. IGDRASOL has the exclusive U.S. distribution rights to Genexol-PM® from Samyang Biopharmaceuticals, a South Korean corporation. 

IGDRASOL is preparing for an "End of Phase 2" meeting with the U.S. Food & Drug Administration (FDA) regarding Cynviloq™ targeted for the first half of 2013.  As a formulation of paclitaxel, Cynviloq™ is potentially eligible for approval via FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (Abraxane®) in its currently approved MBC and NSCLC indications. Abraxane® recently demonstrated overall survival benefit in a pivotal phase 3 study as a first line combination therapy with gemcitabine in advanced pancreatic cancer. Abraxane® sales exceeded $400 million in MBC in fiscal 2012, and are projected to achieve peak sales over $1.6 b
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sorrento Therapeutics Awarded Third Phase I STTR Grant
2. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
3. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
4. Relmada Therapeutics Announces LevoCap ER Development Progress
5. Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
6. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
8. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
10. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
11. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014   Acutus Medical, ... invasive real-time 3D Cardiac Chamber Imaging and Dipole Density ... / or sustain complex cardiac arrhythmias, including atrial fibrillation, ... continue developing its imaging/mapping system as well as bring ... allow Acutus Medical to complete work on the AcQMap ...
(Date:9/30/2014)... , Sept. 30, 2014 In 2011, approximately ... abused prescription pain relievers (e.g. opioids). 1 ... maintenance treatment, which entails the use of buprenorphine, buprenorphine/naloxone, ... treatments are important when developing and improving care management ... benefit manager Prime Therapeutics LLC (Prime). ...
(Date:9/30/2014)... , Sept. 30, 2014  Life Science Angels ... on supporting promising emerging biotech, medical device, genomics, ... the Top Angel Investment Group in the U.S.  ... best performer out of 370 angel groups analyzed ... network strength (connections), selection aptitude and brand recognition.  ...
Breaking Medicine Technology:Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3Life Science Angels Ranked the Top Angel Investment Group in the U.S. 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 3
... Thousands of jobs in Ohio supported by the biopharmaceutical ... such as imposing new taxes in the Medicare prescription ... From research to technical work, manufacturing to construction ... services, the biopharmaceutical sector supports a broad array of ...
... 27, 2011 Codexis, Inc. (Nasdaq: CDXS ... of a joint development agreement to develop an improved ... is Brazil,s largest sugar and ethanol producer.   ... Codexis will deploy the Codexis CodeEvolver™ directed evolution technology ...
Cached Medicine Technology:Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 3Codexis, Raizen to Develop First Generation Ethanol 2Codexis, Raizen to Develop First Generation Ethanol 3
(Date:9/30/2014)... Pittsburgh School of Dental Medicine have been awarded a ... Dental and Craniofacial Research, part of the National Institutes ... roots of cleft lip and cleft palate and to ... the Philippines and Pennsylvania. , Orofacial clefts (OFCs), ... that can form when a baby,s mouth doesn,t develop ...
(Date:9/30/2014)... that some stickleback fish fathers can have long-term effects ... fish dads cause their offspring to behave in a ... behavioral changes are accompanied by changes in gene expression, ... in the Proceedings of the Royal Society B: ... that moms are very important for their offspring," said ...
(Date:9/30/2014)... RISC Networks Corporation, the leader ... data center, cloud and core network infrastructure. RISC ... of helping more than 5,000 businesses solve complex ... as IT infrastructure transformation, cloud IaaS and data ... engagement rates and partner growth seen in 2014 ...
(Date:9/30/2014)... 30, 2014 Speaking on this occasion, ... observed ‘Nursing Conference’ as a remarkable event, which brings ... medical and clinical research and diagnostic companies, leading universities ... a perfect platform to share experience, foster collaborations across ... world. Nursing Conference is a forum to explore issues ...
(Date:9/30/2014)... 2014 MyMobileUni seeks to partner globally ... have similar shared vision to transform individuals and empower ... (MMU):, , to impact ... all ages , to have focused channels ... to promote equal access to education and ...
Breaking Medicine News(10 mins):Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 3Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 2Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 3
... Dec. 7 Transcept Pharmaceuticals,Inc. today announced that Glenn ... an expert panel on "Drug Development in a,Changed Environment" ... Westin New York Hotel at Times Square on Thursday, ... multi-company panel will be moderated by Ken Trbovich, Vice,President, ...
... Ventures, a health and life,sciences focused venture capital firm ... of the firm., "We are pleased to name ... Partner of Radius. "David has demonstrated an outstanding,ability to ... have his,energy and continued contribution as we develop Radius ...
... one of the commonest surgical procedures performed on ... both physical and psychological harm, while recent evidence ... debate the issue in this weeks BMJ. , ... infant circumcision, yet ritual (non-therapeutic) male circumcision continues ...
... inadequate and should be replaced with charters of health ... But even these raise ethical tensions, says Harald Schmidt, ... Medical Association (BMA) recently called for a charter setting ... Service and what patients can expect from the NHS. ...
... 7 Bond,Laboratories, Inc. (OTC Bulletin Board: BNDB), a ... file with the NASD to implement,a 2-for-1 forward split ... as of the record date will receive,two (2) shares ... For,example, shareholders owning 5,000 shares prior to the stock ...
... REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, December 7, ... in,the development of microRNA-based diagnostics and therapeutics, announced,today that ... Rosetta Genomics,will present at RBC Capital Markets 2007 Healthcare ... the Westin Hotel in New York., A live ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference 2Health News:Is infant male circumcision an abuse of the rights of the child? 2Health News:Concept of patients' charters 'inadequate' 2Health News:Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2007 Healthcare Conference 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: